 Arcturus Therapeutics Holdings Inc NASDAQ: ARCT provided updated data from its Phase 12 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose 5 mcg booster. The study also exhibited that booster vaccination generated. 